Radiotherapy combination opportunities leveraging immunity for the next oncology practice.
Fernanda G Herrera, Jean Bourhis, George Coukos
https://pubmed.ncbi.nlm.nih.gov/27570942/Actively Recruiting
Led by Shanghai Chest Hospital · Updated on 2026-01-22
100
Participants Needed
2
Research Sites
52 weeks
Total Duration
Researchers are investigating the potential benefits of combining low-dose radiotherapy LDRT and conventionally fractionated radiotherapy CFRT with first-line anti-PD-1 immunochemotherapy in treating metastatic esophageal squamous cell carcinoma ESCC. This phase II multicenter study aims to evaluate the safety, feasibility, and effectiveness of this combined approach compared to standard immunochemotherapy alone. The study begins with a safety run-in phase to ensure treatment safety before proceeding to a randomized controlled phase. The study has two phases Phase IIa is a safety run-in where about 20-25 patients receive the combination of LDRT, CFRT, and immunochemotherapy to assess safety and feasibility. If safety criteria are met, Phase IIb randomly assigns participants to either an experimental group receiving PD-1 inhibitor plus chemotherapy with LDRT and CFRT, or a control group receiving PD-1 inhibitor plus chemotherapy alone. Treatments include PD-1 inhibitors given every three weeks, chemotherapy with paclitaxel and platinum agents over four cycles, and specific radiotherapy dosing schedules targeting tumors and metastatic lesions. Participants will be closely monitored through regular assessments including safety evaluations up to 30 days after treatment, and progression-free survival up to 36 months after randomization. Researchers will also track overall survival and the incidence of severe treatment-related side effects over one year. The study aims to understand how adding radiotherapy affects treatment outcomes and safety in metastatic ESCC, with ongoing observation throughout the study period.
CONDITIONS
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
W
Wen Yu, M.D
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shanghai Chest Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 weeks (4 cycles every 3 weeks plus radiotherapy starting from cycle 5 if applicable)
Participants in the safety run-in cohort receive a combination of low-dose radiotherapy, conventionally fractionated radiotherapy, PD-1 inhibitor immunotherapy, and chemotherapy to evaluate safety and feasibility of the treatment regimen.
Weekly visits during treatment cycles
Duration - Until disease progression, unacceptable toxicity, or up to 2 years
Participants are randomly assigned to receive PD-1 inhibitor immunotherapy plus chemotherapy, with or without low-dose and conventionally fractionated radiotherapy as first-line treatment for metastatic esophageal squamous cell carcinoma.
Treatment visits every 3 weeks during chemotherapy cycles; radiotherapy visits starting from the fifth immunotherapy cycle for those in the radiotherapy arm
Duration - Up to 36 months
Participants are monitored for progression-free survival, overall survival, and treatment safety for up to 36 months after randomization.
Periodic follow-up visits as scheduled by the study
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Fernanda G Herrera, Jean Bourhis, George Coukos
https://pubmed.ncbi.nlm.nih.gov/27570942/Huiyan Luo, Jin Lu, Yuxian Bai...
https://pubmed.ncbi.nlm.nih.gov/34519801/Zhihao Lu, Junye Wang, Yongqian Shu...
https://pubmed.ncbi.nlm.nih.gov/35440464/Jong-Mu Sun, Lin Shen, Manish A Shah...
https://pubmed.ncbi.nlm.nih.gov/34454674/Narek Shaverdian, Aaron E Lisberg, Krikor Bornazyan...
https://pubmed.ncbi.nlm.nih.gov/28551359/Zi-Xian Wang, Chengxu Cui, Jun Yao...
https://pubmed.ncbi.nlm.nih.gov/35245446/Fernanda G Herrera, Catherine Ronet, Maria Ochoa de Olza...
https://pubmed.ncbi.nlm.nih.gov/34479871/Yue Li, Lin Lin, Jun Liu...
https://pubmed.ncbi.nlm.nih.gov/37937444/Limei Yin, Jianxin Xue, Rui Li...
https://pubmed.ncbi.nlm.nih.gov/32417411/Willemijn S M E Theelen, Heike M U Peulen, Ferry Lalezari...
https://pubmed.ncbi.nlm.nih.gov/31294749/Shanghai Chest Hospital
Lead Sponsor